[3P-0974] Drug screening to identify molecular targets for Ras activated cancer cells using chemical library

〇Iwao Shimomura^1,2, Akira Yokoi¹, Yusuke Yamamoto¹, Yuji Tada², Koichiro Tatsumi², Takahiro Ochiya¹ (1.Div. Mol. Cell Med., Natl. Cancer Ctr. Res. Inst., 2.Dept. of Resp., Grad. Sch. of Med., Univ. of Chiba)

ConBio2017

[3P-0975] Analysis of the metastasis process of scirrhous gastric carcinoma by multicolor fluorescent imaging

〇Ayaka Nakabo^1,2, Kiyoko Fukami², Hideki Yamaguchi¹ (1.Dept. of Cancer Cell Res., Sasaki Inst., Sasaki Foundation, 2.Lab. of Genome and Biosignals, Tokyo Univ. of Pharm. and Life Sci.)

ConBio2017

[3P-0976] Involvement of Keap1-Nrf2 pathway on expression of MDR-1 in the doxorubicin resistance of K562 human leukemia cells

〇Shin Yomogida¹, Akimasa Someya², Saiko Kazuno³, Takashi Ueno³, Yoshiki Miura³, Syu-ichi Kanno¹, Ayako Tomizawa¹, Akiyoshi Hara¹, Tsutomu Fujimura⁴ (1.Dept. of Clinical Pharmacotherapeutics, Tohoku Med. and Pharm. Univ., 2.Dept. of Host Defense and Biochem. Res., Juntendo Univ., Sch. of Med., 3.Lab. of Proteomics and BioMol. Sci., R. S. C., Juntendo Univ., Grad. Sch. of Med., 4.Lab. of Bioanalytical Chem., Tohoku Med. and Pharm. Univ.)

ConBio2017

[3P-0977] Expression levels of metabolic enzyme associated with 5-FU in extramammary Paget disease.

〇Ikko Kajihara¹, Yuki Nakamura¹, Hironobu Ihn¹ (1.Dept. Dermatol. Kumamoto Univ.)

ConBio2017

[3P-0978] Mint3 controls pancreatic cancer cell proliferation

〇Hitomi Yanaizu¹, Akane Kanamori¹, Takeharu Sakamoto¹, Yoshinori Murakami¹ (1.Div. Mol. Path., Inst. Med. Sci., Univ. of Tokyo)

ConBio2017

[3P-0979] Ectopic expression of the CDK inhibitor p21Cip1 enhances cancer specific E2F activity and increases cancer cell-specific cytotoxic gene expression mediated by the ARF tumor suppressor promoter

〇Kenta Kurayoshi¹, Kiyoshi Ohtani¹ (1.Dept. Biomed. Chem., Sch. Sci. & Tech., Kwansei Gakuin Univ.)

ConBio2017

[3P-0980] Integrative control of tumor environment by versatile photoimmunotherapy

〇Naoto Shirasu¹, Hiromi Yamada¹, Hirotomo Shibaguchi¹, Motomu Kuroki², Masahide Kuroki¹, Shin'ichiro Yasunaga¹ (1.Dept. of Biochem., Fac. of Med., Fukuoka Univ., 2.Sch. of Nurs., Fac. of Med., Fukuoka Univ.)

ConBio2017

[3P-0981] Creation of novel anticancer inhibitors targeting nicotinamide phosphoribosyltransferase, the rate limiting enzyme of NAD^＋ biosynthetic pathway

〇Kiyotaka Katsuragi¹, Yasunobu Asawa², Akira Sato¹, Yoko Ogino¹, Yusuke Takai¹, Atsushi Yoshimori³, Takahiro Oyama⁴, Hideaki Abe⁴, Hiroyuki Nakamura², Seiichi Tanuma¹ (1.Fac. of Pharm. Sci., Tokyo Univ. of Sci., 2.Inst. of Innovative Res., Tokyo Tech, 3.Inst. for Theoretical Med., Inc., 4.Hinoki Shinyaku Co., Ltd)

ConBio2017

[3P-0982] A novel regulatory mechanism of PARP1 protein: Apply to cancer therapy

〇Mika Owaki¹, Yuka Ishizaki¹, Yuri Kakiyama¹, Masaki Kobayashi^1,2, Yuka Sudou^1,2, Naoyuki Okita³, Yoshikazu Higami^1,2 (1.Mol. Pathol. and Metab. Dis., Fac. of Pharm. Sci., Tokyo Univ. of Sci., 2.Tra.Re. Cen, Re. Ins. of Sci and Tech, Tokyo Univ. of Sci , 3.Sasaki Ins, Sasaki Fou)

ConBio2017

[3P-0983] The more the number of myeloid-derived suppressor cells, the more can tumor metastases be increased?

〇Xuefeng Jing¹, Takahiro Sawada¹, Takashi Sonoki², Natumi Hayashi¹, Kazumi Nakamatu¹, Masayasu Miyajima³, Kazushige Sakaguchi¹ (1.Dept. of Mol. Cell Bio. and Mol. Med., Inst. Advanced Med., Wakayama Med. Univ., 2.Dept. of Hematology/Oncology, Wakayama Med. Univ., 3.Laboratory Animal Center, Wakayama Med. Univ.)

ConBio2017